Calcitonins are 32-amino acid peptide hormones with both peripheral and central actions mediated via specific cell surface receptors, which belong to the class II subfamily of G protein-coupled receptors. Understanding receptor function, particularly in terms of ligand recognition by calcitonin receptors, may aid in the rational design of calcitonin analogs with increased potency and improved selectivity. To directly identify sites of proximity between calcitonin and its receptor, we carried out photoaffinity labeling studies followed by protein digestion and mapping of the radiolabeled photoconjugated receptor. . These results provide the first direct demonstration of a contact domain between salmon calcitonin and its receptor and will contribute toward modeling of the calcitonin-receptor interface.
peripheral and central tissues, and CTs exert a wide range of actions including modulation of ion excretion in the kidney, inhibition of appetite, and gastric acid secretion via both peripheral and central mechanisms as well as affecting embryological implantation and development and sperm function (1) (2) (3) . CTs, through their action on osteoclasts and to a lesser extent in the kidney, are widely used clinically in the treatment of bone-related disorders such as hypercalcemia of malignancy and osteoporosis but are most effective in conditions that have high bone turnover such as Paget's disease (1, 2) .
CT peptides, derived from different species, fall into three broad classes according to structural and biological similarities: teleost/avian, exemplified by salmon CT (sCT); artiodactyl; and rodent/human. Of these, the teleost/avian class has the highest affinity and efficacy, although the relative potency of CTs varies according to the species of receptor under study (1, 4) . As a consequence of its higher potency and in vivo stability, sCT is the most common form of CT used therapeutically.
The CTR is a member of the class II subfamily of G proteincoupled receptors, which includes the receptors for peptide hormones such as parathyroid hormone (PTH) and PTH-related protein, secretin, vasoactive intestinal polypeptide, and glucagons (5) . These receptors exhibit homology with each other and have a number of common structural features including a large amino-terminal domain that contains at least one site of N-linked glycosylation and 6 conserved cysteines that yield a common pattern of disulfide bonding (6, 7) . The human CTR has two common splice variants that differ by the absence or presence of a 16-amino acid insert in intracellular domain 1; these receptors have been designated hCTRa and hCTRb by the IUPHAR receptor nomenclature subcommittee (8) . Of these two variants, hCTRa is the most prevalent isoform (8 -10) .
Little is known about the molecular nature of the interaction between CT and its receptor, with only limited data from NH 2 -terminal domain exchange chimeras between CTR and either the glucagon receptor (11, 12) or the PTH1 receptor (13) . These have provided preliminary evidence for a prominent role for the NH 2 terminus in high affinity ligand binding and for overlap in the mode of interaction between CT with its receptor and the interaction of other class II ligands and their receptors.
To provide direct information about the nature of the interface between peptides and their respective receptors, a number of laboratories have adopted a photoaffinity scanning approach that relies on the spatially restricted (within 3.1 Å) crosslinking of photolabile amino acids within peptide ligands and their cognate receptors (14) . This approach has proved successful in providing constraints on the relative orientation of peptides and receptors for at least four class II peptide hormone receptors (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) .
In this study we have developed a photolabile derivative of sCT, substituted with p-benzoyl-L-phenylalanine (Bpa) at amino acid 19 for photoaffinity labeling of the hCTRa. Salmon CT was chosen as the template molecule because of its wide use clinically and its high affinity and efficacy at all CTRs (1) (2) (3) . Using this molecule we have identified a short domain in the NH 2 terminus of the receptor close to the transmembrane domain, delimited by Cys 134 and Lys 141 , as the site of covalent interaction. The current work provides the first constraint in defining the interface between sCT and its receptor.
EXPERIMENTAL PROCEDURES

Materials
Cyanogen bromide (CNBr), protein G-agarose beads, 3-isobutyl-1-methylxanthine, forskolin, dithiothreitol, and iodoacetamide were purchased from Sigma. Sequencing grade endoproteinases Lys-C and Asp-N, N-glycosidase F, and protease inhibitor mixture tablets were obtained from Roche Applied Science. Salmon CT and all amino acid derivatives were synthesized by Auspep (Parkville, Australia). Na 125 I(specific activity of 2,200 Ci/mmol) was from Amersham Biosciences.
125 I-Goat anti-mouse immunoglobulin G antibody (specific activity 1,035 Ci/mmol) was obtained from PerkinElmer Life Sciences. Bovine serum albumin (BSA) was from ICN (Costa Mesa, CA). Penicillin G/streptomycin was from Multicell Technologies (Warwick, RI). Dulbecco's modified Eagle's medium, fetal bovine serum, HEPES, Fungizone, and trypsin together with LipofectAMINE reagents and protein molecular mass markers were from Invitrogen. Tissue culture disposables and plasticware were purchased from Falcon (Bedford, MA). 12CA5 mouse monoclonal antibody directed against the hemagglutinin (HA) epitope was purified from hybridoma cells via a Hi-Trap protein G column (Amersham Biosciences) according to the manufacturer's instructions. Lysine residues at positions 11 and 18 in the native sCT sequence were replaced with arginines to render the ligand resistant to enzymatic cleavage by endoproteinase Lys-C; this substitution does not alter activity of the peptide (29) . In general, the procedure for analog synthesis was as follows.
Synthesis of the
Solid Phase Peptide Synthesis-A 0.2-mmol scale was used with the continuous flow Fmoc-polyamide method and a MilliGen 9050 automated synthesizer as described previously (30) . Fmoc-PAL-PEG-PS resin was used as the solid support to generate a COOH-terminal peptide-amide. Amino acid side chain protection was afforded by tertbutyl esters and ethers for Glu, Ser, Thr, and Tyr, trityl for Asn, Gln, His, and Cys, and 2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl for Arg. Residue 19 was introduced manually via its Fmoc-p-benzoylphenyalanine derivative. All amino acid derivatives were activated in situ with 2-(1H-benzotrazole-1-yl)-1,1,3,3-tetramethylronium hexafluorophosphate/N,NЈ-diisoethylpropylamine in dimethyl formamide. Each acylation was of 30-min duration, and subsequent N ␣ -Fmoc deprotection was with 20% piperidine in dimethyl formamide. After synthesis, the peptide was separately cleaved and deprotected by a 3-h treatment with 95% trifluoroacetic acid, 3% anisole, 1% triethylsilane, 1% phenol (v/v/v/w) at room temperature. The crude cleaved peptide was precipitated from ice-cold ether and freeze dried.
Folding and Oxidation-The crude S-reduced peptide was treated with 20% aqueous dimethyl sulfoxide in 5% aqueous acetic acid (31) . Oxidation was monitored by analytical reversed phase high performance liquid chromatography (HPLC) on a Vydac C18 column (Hesperia) using a gradient of CH 3 CN in 0.1% aqueous trifluoroacetic acid for 21 h. The reaction was stopped by further acidification with neat trifluoroacetic acid. Peptide purification was by preparative reversed phase HPLC with a Vydac C18 column.
Characterization-Peptide purity was confirmed by analytical reversed phase HPLC and matrix-assisted laser desorption ionization time-of-flight mass spectrometry using a Bruker Biflex instrument (Bremen, Germany) 
Radioiodination of Peptides
Radiolabeled sCT and [Bpa 19 ]sCT (specific activity ϳ700 Ci/mmol) were prepared by the chloramine-T method as described previously (32) . The iodinated peptides were purified using silica QUSO G32 (North America Silica Co.), washed twice with H 2 O, and eluted with 20% acetone and 1% acetic acid.
Receptor Mutagenesis and Construction of HA-tagged hCTR
cDNA of the hCTRa isoform was excised from the pZEM228cc expression vector (10) using the restriction enzymes HindIII and BamHI and subcloned into the multicloning site of the mammalian expression vector pcDNA3.1zeo ϩ (Invitrogen). The receptor was mutated to introduce a unique AgeI restriction site at amino acid 23, immediately following the predicted signal peptide cleavage site, using site-directed mutagenesis (QuikChange site-directed mutagenesis kit; Stratagene). To create NH 2 -terminal double epitope tags, complementary oligonucleotides that contained two HA epitope peptide sequences flanked by AgeI restriction sites, 5Ј-GCTGCTGCACCGGTCCCATATGATGTACC-AGATTATGCACCAT ATGATGTACCAGATTATGCCACCGGTGCTG-CTGCT-3Ј and 5Ј-AGCAGCAGCACC GGTGGCATAATCTGGTACATC-ATATGGTGCATAATCTGGTACATCATATGGGACCGGTGCAGCAG-C-3Ј, were annealed by heating at 95°C, then gradually cooled and digested with AgeI restriction enzyme. The AgeI-digested doublestranded oligonucleotides were purified and ligated into AgeI-digested, mutated pCDNA3.1zeo
ϩ :hCTRa to generate the "wild-type HA-hCTRa" construct. At each step, the sequence integrity of the constructs was verified using PCR dideoxynucleotide chain termination sequencing.
The following point mutations were introduced, by QuikChange sitedirected mutagenesis, into wild-type HA-hCTRa: L90M, V108M, V117M, M133A, M133L, C134A, N135A, A136V, F137A, T138A, P139A, E140A, K141A, M346L, and M367L. Selected clones were chosen for plasmid isolation (Qiagen; La Jolla, CA), and the presence of mutations was confirmed by nucleotide sequencing (Australian Genome Research Facility, Parkville, Australia).
Cell Cultures and DNA Transfections
COS-7 cells were routinely cultured in Dulbecco's modified Eagle's medium supplemented with 5% heat-inactivated fetal bovine serum, 100 units/ml penicillin and 100 g/ml streptomycin, HEPES, and Fungizone at 37°C in a humidified atmosphere of 95% air and 5% CO 2 . For radioligand receptor binding assay and analysis of cell surface receptor expression, COS-7 cells were seeded into 24-well plates. For crosslinking studies, COS-7 cells were grown in 6-well plates for small scale, and in 60-cm 2 dishes or 140-cm 2 dishes for large scale experiments. Once the cell monolayers were at 95% confluence, cells were transfected with LipofectAMINE using 100 ng, 500 ng, 3 g, and 7 g of plasmid DNA in 24-well plates, 6-well plates, 60-cm 2 and 140-cm 2 dishes, respectively according to the manufacturer's protocol. All transient transfections were performed with either wild-type or mutant HA-hCTRa.
Receptor Binding Assay
Transiently transfected COS-7 cells were grown to confluence in 24-well plates. The cells were incubated with either ϳ90 pM 
cAMP Assay
Intracellular cAMP assay was performed in 384-well plates using the Alpha Screen cAMP kit (PerkinElmer Life Sciences). In brief, transiently transfected COS-7 cells in 60-cm 2 dishes were harvested, counted, and resuspended into stimulation buffer (phenol red free medium, 0.1% BSA, 1 mM 3-isobutyl-1-methylxanthine) and preincubated at 37°C for ϳ20 min. Cells (10,000 cells/well) were then incubated at 37°C for 30 min in the absence and presence of increasing concentration of agonists, either sCT or [Bpa 19 ]sCT. After incubation, anti-cAMP acceptor beads that were prepared in lysis buffer (5 mM HEPES, 0.3% Tween 20, 0.1% BSA) were added to all wells and incubated at room temperature for 30 min in the dark. The detection mix of biotinylated cAMP/streptavidin donor beads, which was preincubated in the dark for 30 min at room temperature, was then added to all wells. The assay plate was incubated overnight at room temperature before reading on a Fusion plate reader (PerkinElmer Life Sciences). For each experiment, forskolin and cAMP dose-response curves were performed in parallel to allow translation of the ␣-screen signal to either cAMP or a percent of the maximum forskolin response. 19 ]sCT. Cells were washed twice with cold 1 ϫ phosphate-buffered saline to remove unbound ligand and then irradiated at a distance of ϳ 5 cm with a 365-nm UV lamp on ice for 30 min. Lysis buffer (0.1 M Tris, 10 mM EDTA, pH 7.3) was then added, and the cells were scraped free of the culture plates and centrifuged at 1,800 ϫ g for 10 min.
Photoaffinity Cross-linking of [Bpa 19 ]sCT to COS-7 Cells Transfected with HA-hCTRa
Immunoprecipitation
To remove potential contamination of signal arising from carry forward of noncovalently bound radioligand, cell lysates were subjected to immunoprecipitation according to the method of Sengstag et al. (33) . For this, 2 g of anti-HA antibody was incubated with each sample to precipitate the [ 125 I-Bpa 19 ]sCT⅐HA-hCTRa complex, with complexes subsequently isolated using protein G-Sepharose beads. For samples not subjected to enzymatic or chemical cleavage, the complexes were eluted directly from the beads using 1 ϫ "reduced" SDS-sample buffer and the eluted proteins were immediately electrophoresed on 10% SDS-PAGE.
Reduction and Alkylation
When necessary, the samples were reduced with 0.5% SDS, 100 mM dithiothreitol, followed by alkylation with 100 mM iodoacetamide for 25 min at room temperature in the dark to break the disulfide bonds irreversibly.
Enzymatic and Chemical Cleavage of the Ligand-Receptor Conjugates
After immunoprecipitation, the ligand-receptor conjugates were subjected to enzymatic or chemical cleavage. For Endo-F deglycosylation, the bead samples were resuspended in 0.15 M Tris, pH 8.8, 1% Nonidet P-40, 0.1% SDS, 0.1% ␤-mercaptoethanol containing 1 unit of N-glycosidase F. For endoproteinase Asp-N digestion, samples were incubated in 50 mM sodium phosphate buffer, pH 8.0, 0.1% SDS, containing 0.04 g/l Asp-N enzyme. For endoproteinase Lys-C digestion, samples were resuspended in 0.1 M Tris, pH 8.5, containing 0.1 g/l Lys-C enzyme. All enzyme-treated samples were incubated at 37°C for 18 h. For CNBr cleavage, samples were incubated in 100 l of 70% trifluoroacetic acid with 10 mg/ml CNBr for 24 h at room temperature, in darkness and under nitrogen. After the incubation period, samples were diluted 5-fold with H 2 O and dried using a vacuum concentrator. Samples were then redissolved in 500 l of H 2 O and dried again.
Electrophoresis and Autoradiography
Radiolabeled samples were assessed using a combination of 10% SDS-PAGE and 16.5% SDS-Tricine or 10 -20% SDS-Tricine (for low molecular mass proteins). After electrophoresis, gels were stained with Coomassie Blue R-250, destained, dried, and exposed to phosphorimaging screens (Fuji-Bas; Tokyo, Japan) for 1-5 days to identify radiolabeled fragments. The relative molecular mass (M r ) of the radiolabeled band was determined, by interpolation, on a plot of the mobility of protein standards versus the log values of their apparent molecular mass.
Cell Surface Expression of Mutated Receptors
Independent monitoring of the cell surface expression of wild-type and mutated HA-hCTRa, in intact COS-7 cells, was performed using the 12CA5 anti-HA antibody as described (34) , with minor modifications. Transfected COS-7 cells were rinsed twice with binding buffer (50 mM Tris-HCl, pH 7.7, 100 mM NaCl, 5 mM KCl, 2 mM CaCl 2 , 1% BSA); cells were then incubated for 3 h at 4°C with binding buffer alone, for nonspecific binding, and binding buffer containing HA-antibody (4 g/ well in 24-well plates) for total binding. Cells were rinsed twice and incubated further with 125 I-goat anti-mouse immunoglobulin G antibody for 3 h at 4°C. Cells were washed twice with phosphate-buffered saline and then lysed with 1 M NaOH. The whole cell lysate was counted in a PerkinElmer Life Sciences ␥-irradiation counter to determine the bound radioactivity. The specific binding of antibody to each mutant was calculated by subtracting the nonspecifically bound radioactivity from total binding.
Statistical Analysis
All experiments were repeated independently at least three times, unless otherwise indicated. The binding curves and cAMP dose-response data are expressed as the mean Ϯ S.D. Data were analyzed using nonlinear regression with the Prism Software package (GraphPad Software, Inc., San Diego). Values in the tables are presented as mean Ϯ S.E., unless otherwise indicated. (Fig. 1, A and B sCT to intact COS-7 cells transiently expressing the HA-hCTRa revealed a single radiolabeled band of M r ϳ72,000, and this band was shifted to M r ϳ51,000 after treatment of the ligand-receptor complex with Endo-F to remove N-linked carbohydrate on the receptor NH 2 terminus (Fig. 2) . These bands are receptor-specific because they were not observed in the nontransfected cells and were completely inhibited by coincubation with excess unlabeled sCT (10 Ϫ7 M) (Fig. 2 ). The receptor mass and level of glycosylation are consistent with the expected mass of the receptor and previously characterized level of receptor glycosylation (35) . The cross-linked receptor-[ 125 I-Bpa 19 ]sCT conjugate was then subjected to a series of chemical and enzymatic cleavages to identify the site of covalent contact between the ligand and receptor.
RESULTS
Pharmacological Characterization of [
The photolabeled HA-hCTRa was digested with CNBr, which cleaves at the COOH terminus of methionine residues, followed by resolution on an SDS-Tricine gel and autoradiography. One specifically labeled band of M r ϳ9,300 was identified. Sequential digestion with Endo-F followed by CNBr did not alter the mobility of the M r 9,000 fragment (Fig. 3) (Fig. 4) , given the molecular mass of the radiolabeled ligand (3.8 kDa) .
Immunoprecipitation of the [ 125 I-Bpa 19 ]sCT⅐HA-hCTRa complex after cleavage with CNBr did not precipitate a radioactive band, indicating that the far NH 2 -terminal end of the receptor was not a site of cross-linking (data not shown). Mutation of Met 346 or Met 367 to leucine, which did not alter either sCT binding or cell surface expression of the receptor, did not shift the migration of the lower molecular mass band, indicating that cross-linking did not occur within extracellular loop 3. However, mutation of Met 133 to either leucine or alanine completely abolished the generation of the M r 9,300 band, with a higher prominent radiolabeled fragment of M r 20,000 formed following sequential digestion with Endo-F and CNBr (Fig. 5) . This band, which was consistent with digestion around the Met 133 site in the wild-type receptor, was equivalent in size to the two accumulated fragments, Gln 60 -Met 133 (8.8 kDa) and Cys 134 -Met 187 (6.1 kDa) (Fig. 4) . In some experiments of the wild-type hCTR, digestion with CNBr was incomplete with weak bands of M r 20,000 and M r 40,000 (Endo-F-treated and untreated, respectively) seen in addition to the predominant band of M r 9,300. These data suggested incomplete digestion around Met 133 in these experiments and was consistent with data from L90M, V108M, and V117M mutants, which demonstrated progressive decreases in molecular mass of the incomplete digestion products (data not shown). 19 ]sCT, the intact photolabeled HA-hCTRa was incubated with the enzyme Asp-N, which digests specifically at the NH 2 -terminal side of aspartic acid residues. Asp-N cleavage yielded two radiolabeled bands after resolution on SDS-Tricine gel: an M r ϳ26,000 fragment in addition to a higher molecular mass band presumably resulting from incomplete digestion. When treated with Endo-F, the electrophoretic mobility of the M r 26,000 band shifted to M r ϳ12,000, demonstrating that it is glycosylated (Fig. 6 ). Only two Asp-N-generated domains on hCTRa contain glycosylation sites (Fig. 7) 19 ]sCT. After cross-linking and immunoprecipitation, the ligandreceptor complexes were treated with Endo-F and subsequently analyzed on a 10% SDS-polyacrylamide gel. Autoradiography revealed a radiolabeled band of M r ϳ72,000 which was shifted to M r ϳ51,000 upon deglycosylation as indicated by arrows. The low molecular mass standards (Bio-Rad) are shown at the left. The autoradiograph is a representative of more than three independent experiments. sCT to the whole COS-7 cells transiently expressing HA-hCTRa was immunoprecipitated and then treated with Endo-F followed by CNBr. The radiolabeled protein was electrophoresed on a 16.5% SDSTricine gel. CNBr digestion of native receptor yielded a prominent fragment of M r ϳ9,300. Sequential digestion with Endo-F followed by CNBr did not alter the mobility of the M r 9,300 fragment. The See Blue molecular mass markers (Invitrogen) are shown at the left. The autoradiograph is a representative of more than three independent experiments.
residues. Digestion of the [ 125 I-Bpa 19 ]sCT⅐HA-hCTRa complex with Endo-Lys-C yielded an M r ϳ20,000 fragment in addition to a higher molecular mass band resulting from incomplete digestion (Fig. 8) . When treated with Endo-F, the electrophoretic mobility of the M r 20,000 band shifted to M r ϳ8,000 (M r ϳ4,000 after subtracting the 3.8 kDa probe), demonstrating that it is glycosylated. Only two Endo-Lys-C-generated domains on HA-hCTRa contain glycosylation sites: Cys 55 -Lys 107 (M r ϳ5,900), which contains one glycosylation site, and His 121 -Lys 141 (M r ϳ2,300), which contains two glycosylation sites (Fig. 9) , suggesting that the latter fragment is the probable site of cross-linking.
Taken together with the CNBr data, the results indicate that [Bpa 19 ]sCT cross-links specifically to a site contained within the small receptor region delimited by residues Cys 134 and Lys 141 of hCTRa. In an attempt to identify individual receptor amino acids involved in the cross-linking, this small region of the receptor was subjected to alanine scanning mutagenesis. Wild-type and mutant receptors were transiently transfected into COS-7 cells and assessed for cell surface expression, binding affinity, and functional response. With one exception, all mutants were fully expressed at the cell surface and displayed equivalent affinity for sCT in 125 I-sCT competition binding studies (Table I) . Likewise, there was little change in either EC 50 (Table I) or E max values (not shown) for sCT-mediated accumulation of cAMP. The exception to this was the C134A mutant, which was very poorly expressed at the cell surface and essentially did not bind or respond to sCT. Cysteine 134 is one of 6 highly conserved cysteine residues in the NH 2 terminus of class II G proteincoupled receptors. Studies with other class II receptors have demonstrated that each of these cysteines forms a disulfide bond that is believed to maintain the topology required for ligand binding and for the receptor to be properly folded and expressed at the cell surface (34, 36, 37) . Thus, lack of functionality of this mutant is not surprising. The data with the other mutants (N135A, A136V, F137A, T138A, P139A, E140A and K141A) demonstrate that conversion to alanine did not functionally affect ligand-receptor interaction. Photoaffinity cross-linking of [ 125 I-Bpa 19 ]sCT to each of the mutated receptors transiently expressed into COS-7 cells gave rise to a band of M r ϳ75,000 (Fig. 10A) , and subsequent digestion with CNBr resulted in a predominant band of M r 9,300 (Fig. 10B) . These radiolabeled fragments were not markedly different from the wild-type receptor, indicating that substitution of individual amino acids with alanine was not sufficient to alter the efficiency of cross-linking.
DISCUSSION
Three primary mechanisms are used to investigate the nature of ligand-receptor interaction: 1) alteration to ligand structure; 2) alteration to receptor structure (e.g. by mutation or formation of receptor chimeras or receptor truncation); and 3) physiochemical investigation of points of contact between the ligand and receptor. Although all three approaches provide potentially important information for understanding of how ligands interface with their receptors, the first two approaches have limitations in the interpretation of data because they can provide only indirect and inferential information about the nature of the bimolecular interaction and cannot precisely define the complementary domains in the apposing partner involved in the interaction. This is particularly true for ligands with diverse pharmacophores such as those for class II G protein-coupled receptors, where significant potential exists for conformational changes to affect sites distal to the point of modification. The third approach provides a mechanism for directly defining the ligand-receptor interface by using photoactive amino acid derivatives spaced along the peptide to define proximity of particular amino acids in the receptor and ligand. This approach has been used successfully in the study of class II receptors including the PTH1 and PTH2 receptors (15) (16) (17) (18) (19) (20) (21) (22) , the secretin receptor (23) (24) (25) (26) (27) , and the vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide (VPAC1) receptor (28) . The constraints provided by these studies have allowed preliminary models of ligand receptor interaction of the PTH1 and secretin receptors to be generated (38, 39) , whereas the initial work with the VPAC1 receptor is generally supportive of homology modeling of the NH 2 -terminal domain of the receptor using a yeast lipase as template (28) .
In this study we have generated an analog of sCT substituted at position 19 of its sequence with the photoactive Bpa moiety. CD and NMR analysis of sCT structure indicate that it forms an amphipathic ␣-helix between amino acids 8 and 22 (40 -43) . Within this context, amino acid 19 is predicted to lie along the hydrophobic face of the helix, and substitution of leucine with the benzoyl-phenylalanine is unlikely to disrupt this structure. Earlier studies with (⑀-p-benzoyl-benzoyl) lysine-substituted sCT analogs have demonstrated that substitution of amino acids 8, 16, and 19 can be tolerated without significant loss of binding affinity (44) , but the utility of these analogs for delineation of binding domains has not been assessed. Pharmacological analysis of the Bpa 19 -substituted analog in the current study demonstrated that it also had similar affinity and only slightly reduced efficacy relative to the native sCT peptide. Photoaffinity cross-linking combined with chemical and enzymatic cleavage and receptor mutagenesis identified the site of cross-linking to the receptor as the fragment Cys 134 -Lys 141 . Delineation of the interaction site was problematic because of incomplete cleavage of the receptor with each of the digestion reagents, although this was less evident for CNBr digestion. Nonetheless, mutagenesis to introduce or remove methionine residues unambiguously placed the site of cross-linking within amino acids Cys 134 -Met 187 . Endo-Lys-C digestion refined this to amino acids 134 -141. Potential reasons for the poor digestion may include steric masking of cleavage sites by surrounding amino acids, low protein solubility in strong dissociating agents (like trifluoroacetic acid), or, in the case of CNBr, oxidation of the methionine residues during protein manipulations (45) . In addition, the NH 2 terminus of the hCTRa (as with other class II receptors) contains 6 conserved cysteines that for PTH1 and corticotropin-releasing factor receptors have been shown to link via disulfide bonds (6, 7) , and these are required for expression of functional receptors (34, 36, 37) . The loss of cell surface receptor expression and functionality of the C134A mutant in the current study is consistent with these findings. Thus, the tight folding of the receptor NH 2 terminus may provide steric hindrance to efficient cleavage at some sites, although, in our hands, reduction and alkylation (not shown) did not improve cleavage efficiency. Salmon CT, when binding to the hCTRa receptor, forms a quasi-irreversible interaction with the receptor over time (46) . Although this binding is reversed under acidic conditions, when covalently bound to the receptor, it is possible that sCT derivatives maintain a degree of conformational constraint on the receptor leading to lower efficiency of receptor cleavage.
Further analysis of the Cys 134 -Lys 141 receptor subdomain via alanine scanning mutagenesis failed to identify specifically the primary site of cross-linking. The lack of resolution with this methodology is not necessarily surprising. The accommodation of the larger Bpa moiety in place of leucine 19, without significant loss of affinity, implies a degree of conformational flexibility within the receptor domain that interfaces with this part of the peptide. Mutation of the native amino acids in the receptor sequence to alanine may have allowed adjacent amino acids to have greater proximity to Bpa 19 of the peptide with consequent maintenance of cross-linking efficiency. In studies of the interaction of [Bpa 23 ]PTH (1-36) with the PTH1 receptor, alanine scanning mutagenesis of the receptor domain involved in cross-linking also failed to abolish photolabeling (21); however, in this case mutation of 2 of the amino acids caused modulation of ligand binding, implicating these receptor residues as important functional contact sites for PTH-related protein (21) . In our study, no significant shift in binding affinity was observed, indicating that sCT does not form functionally important contacts with this part of the receptor. Recent work by Dong and colleagues 2 with a Bpa 16 analog of hCT has shown that amino acid 16 has spatial proximity to Phe 137 of the hCTRa, which lies within the short domain that we identified as the site of interaction of 19 ]sCT in intact COS-7 cells transiently expressing HA-hCTRa was immunoprecipitated and then treated with Endo-F, followed EndoLys-C enzyme. The radiolabeled protein was electrophoresed on a 16.5% SDS-Tricine gel. Endo-Lys-C digestion yielded two fragments, one migrating at approximately M r 40,000 and the other at M r ϳ20,000. When treated with Endo-F, these bands were shifted to M r ϳ30,000 and M r ϳ8,000, respectively. The See Blue molecular mass markers are shown at the left. The results shown are representative of three different experiments.
tides (42, 43) . A similar observation was made for the spatial proximity sites of Bpa 18 -and Bpa 22 -substituted secretins, which are also predicted on NMR structure (47, 48) to lie ϳ1 helical turn apart. These analogs interacted with arginine 14 and leucine 17 of the secretin receptor, respectively (25, 26) .
There is little direct information available on the mechanism underlying the interaction of CT with its receptor, with most information deriving from studies of chimeras between CT receptors and either the glucagon receptor (11, 12) or the PTH1 receptor (13) . NH 2 -terminal domain exchange between the glucagon receptor and hCTRa confirmed that the NH 2 -terminal domain is the principal high affinity binding domain of the 16 ]hCT analog 2 provide direct support for this mode of ligand receptor interaction. Chimeras between the CTR and PTH1 receptor provide additional evidence for conservation in the mode of ligand-receptor interaction for these class II receptors (13); NH 2 -terminal domain exchange of these two receptors led to a significant loss of interaction with the "native" CT and PTH peptides that was recovered with chimeric sCT/PTH peptides. Chimeric sCT/hCT peptides have demonstrated that the higher affinity of sCT in binding to the CTRs involves residues within the COOH terminus (amino acids 22-32) of the peptide (4). Amino acids within this domain likely interact with both the NH 2 terminus (as this domain is required for high affinity binding), and also with the receptor trunk because sCT (8 -32) potently antagonizes agonist responses in the hCTRa chimera incorporating the glucagon NH 2 terminus (11). Further photoaffinity scanning analyses are required to test these hypotheses empirically and to provide a more detailed model of CT-receptor interaction.
In conclusion, we have identified a short segment of the hCTRa, close to the border with transmembrane domain 1, which is proximal to amino acid 19 of sCT. The work provides a valuable constraint for molecular modeling of the interface between sCT and its receptor. Further work is required to identify additional constraints that will enable the generation of a working model of CT-receptor interaction and to determine the degree to which the mode of interaction of class II peptide ligands and their cognate receptors overlaps. ]sCT to either wild type-HA-hCTRa or mutated receptors (C134A, N135A, V136A, F137A, T138A, P139A, E140A, K141A) transiently transfected into COS-7 cells. A, after cross-linking, the cell lysate was immunoprecipitated and subsequently electrophoresed on a 10% SDSpolyacrylamide gel. The conjugates of ligand and mutated receptors revealed a band of M r ϳ75,000, which was not observed in the nontransfected cells (NT). The M r 75,000 band was not different from that seen with the wild-type (WT) receptor, indicating that substitution of individual amino acids with alanine was not sufficient to alter the efficiency of cross-linking. The low molecular mass standards (Bio-Rad) are shown at the left. The autoradiograph is a representative of two independent experiments. B, CNBr digestion of ligand-receptor conjugates resolved on a 16.5% SDS-Tricine gel yielded a prominent fragment of M r ϳ9,300 for all alanine scanning mutants, which were not different from the digestion seen with the wild-type receptor, further emphasizing that substitution of individual amino acids with alanine was not sufficient to alter peptide binding. The location of the See Blue molecular mass markers is shown at the left. The autoradiograph is a representative of three independent experiments.
